This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
The investment will improve equipment efficiency and increase safety standards at its Lestrem site
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
The facility will produce 150 million vaccine doses per year
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Over the next three years, BASF will continue to support Beyond Suncare by supplying the required raw materials free of charge and by providing technical expertise to further improve the formulation
Subscribe To Our Newsletter & Stay Updated
